Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease

Clinical Drug Investigation

Volumn 27, Issue 4, 2007, Pages 287-296

  Scholten, Theo ^a   Teutsch, Iris ^b   Bohuschke, Martina ^b   Gatz, Gudrun ^b  

^a University Hospital of Witten Herdecke   (Germany)

^b ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENDOSCOPY; ENTEROCOLITIS; EPIGASTRIC PAIN; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ODYNOPHAGIA; OSTEOARTHRITIS; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP DISORDER; TONSILLITIS; TREATMENT OUTCOME; VARICOSIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33947321275     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727040-00008     Document Type: Article

References (38)

1. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 24-9
2. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med 1999; 72 (2-3): 181-94
3. Carlsson R, Holloway RH. Endoscopy-negative reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14 (5): 827-37
4. Dimenas E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8-13
5. Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94 (7): 1782-9
6. Wiklund IK, Glise H. Quality of life in different gastrointestinal conditions. Eur J Surg Suppl 1998; (582): 56-61
7. Kulig M, Leodolter A, Vieth M. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18 (8): 767-76
8. Glise H, Hallerback B, Wiklund I. Quality of life: a reflection of symptoms and concerns. Scand J Gastroenterol Suppl 1996; 221: 14-7
9. Dent J, Brun J, Fendrick AM, et al. on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-16
10. Klinkenberg-Knol EC, Festen HP, Meuwissen SG. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49 (5): 695-710
11. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10 (2): 119-24
12. Galmiche JP, Letessier E, Scarpignato C. Treatment of gastro-oesophageal reflux disease in adults. BMJ 1998; 316 (7146): 1720-3
13. Klinkenberg-Knol EC, Festen HP, Jansen JB. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121 (3): 161-7
14. Vigneri S, Termini R, Leandro G. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333 (17): 1106-10
15. Dent J. The role of the specialist in the diagnosis and short and long term care of patients with gastroesophageal reflux disease. Am J Gastroenterol 2001; 96 Suppl. 8: S22-6
16. Maton PN. Omeprazole. N Engl J Med 1991; 324 (14): 965-75 17. Inadomi JM. On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations. Pharmacoeconomics 2002; 20 (9): 565-76
17. Lee JM, O'Morain CA. Trends in the management of gastro-oesophageal reflux disease. Postgrad Med J 1998; 74 (869): 145-50
18. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49 (443): 463-4
19. Scholten T, Pustlauk U, Sander P, et al. Pilot study of on-demand therapy with pantoprazole 20mg for long-term treatment in patients with mild gastro-oesophageal reflux disease. Clinical Drug Invest 2005; 25 (10): 633-42
20. Scholten T, Dekkers CPM, Schütze K, et al. On-demand therapy with pantoprazole 20mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. Digestion 2005; 72: 76-85
21. Janssen W, Meier E, Gatz G, et al. Effects of pantoprazole 20mg in mild gastroesophageal reflux disease: once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term. Curr Ther Res 2005; 66 (4): 345-63
22. Kaspari S, Kupcinskas L, Heinze H, et al. Pantoprazole 20mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005; 17 (9): 935-41
23. O'Connor JB, Provenzale D, Brazer S. Economic considerations in the treatment of gastroesophageal reflux disease: a review. Am J Gastroenterol 2000; 95 (12): 3356-64
24. Gerson LB, Robbins AS, Garber A. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95 (2): 395-407
25. Lundell LR, Dent J, Bennett JR. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45 (2): 172-80
26. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98 Suppl. 3: S8-S14
27. Gillessen A, Beil W, Modlin IM, et al. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38 (4): 332-40
28. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18 (6): 587-94
29. Kovacs TO, Wilcox CM, DeVault K, et al. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 2002; 16 (12): 2043-52
30. Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96 (10): 2849-57
31. Kaspari S, Biedermann A, Mey J. Comparison of pantoprazole 20mg to ranitidine 150mg b.i.d. in the treatment of mild gastroesophageal reflux disease. Digestion 2001; 63 (3): 163-70
32. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32 (10): 974-9
33. Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J Gastroenterol 2003; 38 (12): 1197-9
34. Frazzoni M, De Micheli E, Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003; 18 (11-12): 1091-8
35. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159 (7): 649-57
36. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999; 45 Suppl. 2: II31-6
37. Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for months. Eur J Gastroenterol Hepatol 2002; 14 (8): 857-63
38. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001; 15 (3): 347-54